Virtus ETF Advisers LLC Cel Sci Corp Transaction History

Virtus ETF Advisers LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $50,647 - $97,958	-19,631 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.93 - $7.7 $4,562 - $8,939	-1,161 Reduced 5.58%	19,631 $77,000
Q4 2021 Feb 14, 2022	BUY	$7.1 - $12.82 $76,907 - $138,866	10,832 Added 108.76%	20,792 $148,000
Q3 2021 Nov 15, 2021	SELL	$7.64 - $12.49 $3,949 - $6,457	-517 Reduced 4.93%	9,960 $109,000
Q2 2021 Aug 10, 2021	SELL	$8.68 - $27.49 $93,197 - $295,160	-10,737 Reduced 50.61%	10,477 $91,000
Q1 2021 May 17, 2021	BUY	$12.0 - $27.64 $4,380 - $10,088	365 Added 1.75%	21,214 $323,000
Q4 2020 Feb 12, 2021	SELL	$11.05 - $16.62 $33,282 - $50,059	-3,012 Reduced 12.62%	20,849 $243,000
Q3 2020 Nov 13, 2020	SELL	$11.69 - $14.54 $38,050 - $47,327	-3,255 Reduced 12.0%	23,861 $304,000
Q2 2020 Aug 05, 2020	SELL	$9.75 - $17.6 $188,477 - $340,225	-19,331 Reduced 41.62%	27,116 $405,000
Q1 2020 May 14, 2020	SELL	$7.54 - $17.05 $51,106 - $115,564	-6,778 Reduced 12.73%	46,447 $536,000
Q4 2019 Feb 13, 2020	BUY	$6.71 - $9.55 $357,139 - $508,298	53,225 New	53,225 $487,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.